Qube Research & Technologies Ltd - INTERCEPT PHARMACEUTICALS IN ownership

INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 130 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q2 2023. The put-call ratio across all filers is 2.13 and the average weighting 0.1%.

Quarter-by-quarter ownership
Qube Research & Technologies Ltd ownership history of INTERCEPT PHARMACEUTICALS IN
ValueSharesWeighting
Q1 2023$1,635,008
+133.5%
121,743
+115.1%
0.01%
+75.0%
Q4 2022$700,080
+213.9%
56,595
+249.9%
0.00%
+100.0%
Q2 2022$223,00016,1740.00%
Other shareholders
INTERCEPT PHARMACEUTICALS IN shareholders Q2 2023
NameSharesValueWeighting ↓
Samsara BioCapital, LLC 234,375$23,623,00022.67%
Boxer Capital, LLC 600,000$60,474,0007.47%
DLD Asset Management, LP 834,600$84,136,0005.77%
GREAT POINT PARTNERS LLC 200,000$20,158,0002.55%
BB BIOTECH AG 575,719$58,027,0001.86%
Elk Creek Partners, LLC 207,657$20,930,0001.74%
ALTRINSIC GLOBAL ADVISORS LLC 277,944$28,014,0001.34%
Sarissa Capital Management LP 54,000$5,442,0001.21%
QCM Cayman, Ltd. 2,181$220,0000.90%
Opus Point Partners Management, LLC 3,534$356,0000.78%
View complete list of INTERCEPT PHARMACEUTICALS IN shareholders